切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2020, Vol. 14 ›› Issue (04) : 278 -283. doi: 10.3877/cma.j.issn.1674-1358.2020.04.003

所属专题: 文献

论著

HBeAg阳性慢性乙型肝炎患者HBV前C/BCP突变/准种与HBeAg和HBV DNA的关系
鲁俊锋1, 李金娥1, 柳雅立1, 金怡1, 马丽娜1, 胡中杰1, 陈新月1,()   
  1. 1. 100069 北京,首都医科大学附属北京佑安医院肝病中心一科
  • 收稿日期:2019-11-24 出版日期:2020-08-15
  • 通信作者: 陈新月
  • 基金资助:
    "十三五"国家科技重大专项课题(No. 2017ZX10201021-001-008、2017ZX10202202-005-010、2017ZX10202201); 青海省重点研发与转化计划(No. 2017-SF-159)

Relationship between HBV pre-C/BCP mutation/quasispecies and HBeAg and HBV DNA in HBeAg positive patients with chronic hepatitis B

Junfeng Lu1, Jin’e Li1, Yali Liu1, Yi Jin1, Lina Ma1, Zhongjie Hu1, Xinyue Chen1,()   

  1. 1. Department of Hepatology, Beijing You’an Hospital, Capital Medical University, Beijing 100069, China
  • Received:2019-11-24 Published:2020-08-15
  • Corresponding author: Xinyue Chen
  • About author:
    Corresponding author: Chen Xinyue, Email:
引用本文:

鲁俊锋, 李金娥, 柳雅立, 金怡, 马丽娜, 胡中杰, 陈新月. HBeAg阳性慢性乙型肝炎患者HBV前C/BCP突变/准种与HBeAg和HBV DNA的关系[J]. 中华实验和临床感染病杂志(电子版), 2020, 14(04): 278-283.

Junfeng Lu, Jin’e Li, Yali Liu, Yi Jin, Lina Ma, Zhongjie Hu, Xinyue Chen. Relationship between HBV pre-C/BCP mutation/quasispecies and HBeAg and HBV DNA in HBeAg positive patients with chronic hepatitis B[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2020, 14(04): 278-283.

目的

探讨HBeAg阳性慢性乙型肝炎(eP-CHB)HBV前C/BCP突变/准种及其与HBeAg、HBV DNA水平的关系。

方法

采用断面研究对2016年1月至2018年12月就诊于首都医科大学附属北京佑安医院的220例eP-CHB患者进行前C/BCP突变检测,其中24例患者进行前C/BCP区扩增、克隆,同步检测血清HBeAg和HBV DNA水平,分析前C/BCP突变/准种的发生情况及其与HBeAg和HBV DNA水平的关系。

结果

220例eP-CHB患者中,HBV前C/BCP总突变率为70.0%(154/220),前C/BCP共同突变率为18.2%(40/220),前C突变率为30.9%(68/220),BCP突变率为57.3%(126/220)。HBV DNA≥ 5 lgIU/ml患者上述4种突变检出率均高于HBV DNA< 5 lgIU/ml者,其中前C/BCP总突变和BCP突变患者差异有统计学意义(χ2 = 5.809、P = 0.016,χ2 = 5.081、P = 0.024)。HBeAg水平越低(< 500 COI、500~1 000 COI和> 1 000 COI共3组患者比较),以上4种突变检出率越高,差异有统计学意义(χ2 = 31.738、17.291、16.263、22.164,P均< 0.001)。HBV DNA≥ 5 lgIU/ml患者中,HBeAg水平越低,以上4种突变检出率越高,差异亦均有统计学意义(χ2 = 40.503、19.654、16.727、29.119,P < 0.001)。准种检测中,前C区高突变组患者HBeAg水平低于低突变组,差异有统计学意义(t = 2.230、P = 0.017),前C、BCP高突变组与低突变组间HBV DNA水平差异无统计学意义(t = 0.624、P = 0.462,t = 0.893、P = 0.317)。

结论

eP-CHB患者中仍存在广泛的前C/BCP突变。高HBV DNA、低HBeAg表达者,前C和BCP突变的发生率较高;前C区突变株在准种中比率高者更影响HBeAg的表达。推测前C/BCP突变可能是eP-CHB出现低HBeAg、高HBV DNA,并导致抗病毒治疗停药后易复发的原因。

Objective

To investigate the pre-C/BCP mutation and quasispecies in patients with hepatitis B virus e antigen (HBeAg) positive (eP-CHB) and the relationship with the levels of HBeAg and HBV DNA.

Methods

The pre-C/BCP mutation was detected in 220 patients with eP-CHB from January 2016 to December 2018 admitted in Beijing You’an Hospital, Capital Medical University by cross-sectional study. Among whom, the pre-C/BCP region in 24 patients was amplified and cloned. Serum HBeAg and HBV DNA levels were detected simultaneously. The pre-C/BCP mutation and quasispecies and the relationship with HBeAg and HBV DNA levels were analyzed, respectively.

Results

Among the 220 patients with eP-CHB, total mutation rate of pre-C/BCP was 70.0% (154/220), co-mutation rate of pre-C/BCP was 18.2% (40/220) and mutation rate of pre-C and BCP were 30.9% (68/220) and 57.3% (126/220), respectively. The detection rates of the above four mutations in patients with HBV DNA ≥ 5 lgIU/ml were all higher than those of patients with HBV DNA < 5 lgIU/ml, the rates of BCP mutation and pre-C/BCP total mutation were significantly different (χ2 = 5.809, P = 0.016; χ2 = 5.081, P = 0.024). The lower HBeAg level was (< 500 COI, 500-1 000 COI and > 1 000 COI), the higher detection rates of the above four mutations were, all with significant difference (χ2 = 31.738, 17.291, 16.263, 22.164; all P < 0.001). Similarly, among the cases with HBV DNA ≥ 5 lgIU/ml, the detection rates of the above four mutations were higher among the cases with lower HBeAg level, with significant differences (χ2 = 40.503, 19.654, 16.727, 29.119; all P < 0.001). In quasispecies detection, HBeAg level of cases with high mutation of the pre-C region was lower than that with low mutation, with significant difference (t = 2.230, P = 0.017). There was no significant difference between HBV DNA levels of cases with high mutation and low mutation of the pre-C region (t = 0.624, P = 0.462) and BCP (t = 0.893, P = 0.317).

Conclusions

There were still extensive pre-C/BCP mutations in eP-CHB. The mutation rates of pre-C and BCP were higher in patients with high HBV DNA and low HBeAg level. The high proportion of pre-C mutants in quasispecies had more influence on HBeAg expression. Combined with the previous studies, it was speculated that the pre-C/BCP mutation may be the cause of low HBeAg and high HBV DNA in eP-CHB and lead to the recurrence after withdrawal of antiviral therapy.

表1 eP-CHB中前C和BCP区突变检测
表2 HBV DNA水平与前C/BCP突变[例(%)]
表3 HBeAg水平与前C/BCP突变[例(%)]
表4 HBV DNA≥ 5 lgIU/ml时HBeAg水平与前C/BCP突变
表5 24例患者HBV前C/BCP区克隆株突变
图1 G1896A高突变组和低突变组患者HBeAg和HBV DNA水平
图2 A1762T/G1764A高突变组和低突变组患者HBeAg和HBV DNA水平
[1]
Jammeh S, Tavner F, Watson R, et al. Effect of basal core promoter and pre-core mutations on hepatitis B virus replication[J]. J Gen Virol,2008,89(Pt 4):901-909.
[2]
Kamijo N, Matsumoto A, Umemura T, et al. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion[J]. World J Gastroenterol,2015,21(2):541-548.
[3]
Li H, She Q, Liu Y, et al. Clinical implication and viral mutation in basal core promoter/pre-core of hepatitis B virus C/D recombinant[J]. Hepatol Int,2018,12(5):447-455.
[4]
Sonneveld MJ, RijckborstV, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology,2012,56(1):67-75.
[5]
Wang XL, Ren JP, Wang XQ, et al. Mutations in pre-core and basic core promoter regions of hepatitis B virus in chronic hepatitis B patients[J]. World J Gastroenterol,2016,22(11):3268-3274.
[6]
Chachá SGF, Gomes-Gouvêa MS, Malta FM, et al. Basal core promoter and precore mutations among hepatitis B virus circulating in Brazil and its association with severe forms of hepatic diseases[J]. Mem Inst Oswaldo Cruz,2017,112(9):626-631.
[7]
Luo Y, Pan M, Ning M, et al. High mutation prevalence of precore and basal core promoter in pregnant women who underwent spontaneous HBeAg seroconversion within one year postpartum[J]. Dig Liver Dis,2020,52(2):199-204.
[8]
Atsama Amougou M, Marchio A, Bivigou-Mboumba B, et al. Enrichment in selected genotypes, basal core and precore mutations of hepatitis B virus in patients with hepatocellular carcinoma in Cameroon[J]. J Viral Hepat,2019,26(9):1086-1093.
[9]
Lu JF, Li JE, Liu YL, et al. Study on post-treatment relapse in HBeAg positive CHB patients[J]. PLoS One,2015,10(11):e0141072.
[10]
中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015年版)[J]. 中国肝脏病杂志(电子版),2015,7(3):1-17.
[11]
戴海梅, 韦嘉. HBeAg阴性乙型肝炎与前C/BCP区变异的相关性[J]. 临床肝胆病杂志,2019(4):879-882.
[12]
Chen CH, Lee CM, Lu SN, et al. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan[J]. J Clin Microbiol, 2005,43(12):6000-6006.
[13]
白丽, 王琳, 徐东平. 234例慢性乙型肝炎患者HBV前C/BCP区突变分析[J]. 实用肝脏病杂志,2009,12(1):14-16.
[14]
Sonneveld MJ, Rijckborst V, Zwang L, et al. Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants[J]. Antiviral research,2013,97(3):312-317.
[15]
Pan CQ, Dai E, Bhamidimarri KR, et al. Clinical features of chronic hepatitis B in treatment-naive Asian patients with positive HBeAg and coexisting precore and/or basal core promoter mutations[J]. J Clin Gastroenterol,2017,51(3):261-267.
[16]
Chuaypen N, Payungporn S, Poovorawan K, et al. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B[J]. Virus Genes,2019,55(5):610-618.
[17]
任玉莲, 宋修光. 慢性乙型肝炎患者病毒准种的研究进展[J/CD]. 中华实验和临床感染病杂志(电子版),2018,12(1):7-10.
[18]
Valaydon ZS, Locarnini SA. The virological aspects of hepatitis B[J]. Best Pract Res Clin Gastroenterol,2017,31(3):257-264.
[19]
张继. HBV cccDNA研究现状与挑战[J]. 临床肝胆病杂志,2019,35(6):1177-1180.
[20]
Wang XL, Ren JP, Wang XQ, et al. Mutations in pre-core and basic core promoter regions of hepatitis B virus in chronic hepatitis B patients[J]. World J Gastroenterol,2016,22(11):3268-3274.
[21]
Choi JW, Ahn SH, Park JY, et al. Hepatitis B e antigen-negative mutations in the precore and core promoter regions in Korean patients[J]. J Med Virol,2009,81(4):594-601
[22]
Scaglioni PP, Melegari M, Wands JR. Biological properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame[J]. Virology,1997,233(2):374-381.
[23]
Moriyama K, Okamoto H, Tsuda F, et al. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precoree promoter with sequence associated with e antigen-seronegative persistent infections[J]. Virology,1996,226(2):269-280.
[24]
Tacke F, Gehrke C, Luedde T, et al. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants[J]. J Virol,2004,78(16):8524-8535.
[25]
Buckwold VE, Xu ZC, Chen M, et al. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on pre-core gene expression and viral replication[J]. J Virol,1996,70(9):5845-5851.
[26]
Tang H, Banks KE, Anderson AL, et al. Hepatitis B virus transcription and replication[J]. Drug News Perspect,2001,14(6):325- 334.
[1] 高明茹, 董晓秋. 声脉冲辐射力成像联合瞬时弹性成像对炎性肝纤维化的诊断价值[J]. 中华医学超声杂志(电子版), 2019, 16(07): 549-554.
[2] 马娟, 唐仕芳, 刘慧敏, 张娅琴, 邓义娟, 汪丽, 李力. 《乙型肝炎病毒母婴传播预防临床指南(2020)》更新要点解读[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(05): 516-526.
[3] 张小曼, 马筱秋, 许正锯, 张纯瑜, 何彩婷. 乙型肝炎病毒逆转录酶区耐药突变对血清乙型肝炎病毒表面抗原水平的影响[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 324-332.
[4] 全敏, 闫改琴, 邢卉春. 可溶性Fas水平在慢性乙型肝炎患者抗病毒应答不佳优化治疗中的变化[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 16-23.
[5] 谢芳, 熊熙, 姚传霞, 孙浩男, 李平, 汪茂荣. 聚乙二醇化干扰素α-2b联合核苷(酸)类似物治疗低水平乙型肝炎病毒表面抗原慢性乙型肝炎患者的临床疗效及影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(04): 247-253.
[6] 高祥, 赵成军, 胡世宏. 年龄-胆红素-国际标准化比率-肌酐评分对乙型肝炎相关慢加急性肝功能衰竭患者短期预后的评估价值[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(02): 108-114.
[7] 郑璇, 张宝, 李世龙, 张晓茹. 150例不同基因型慢性乙型肝炎患者逆转录聚合酶区耐药变异位点特征及耐药影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(02): 82-89.
[8] 钱舒然, 谭婧文, 王萌婕, 张思航, 杨镇英, 何越峰, 李晖. 致癌相关环状RNA在慢性乙型肝炎病毒感染者的表达及临床意义[J]. 中华实验和临床感染病杂志(电子版), 2021, 15(02): 78-85.
[9] 张媛媛, 殷倩倩, 杜鹏程, 丁奕博, 韩俊燕, 林倩茹, 马丽英. 评价全血DNA二代测序共有序列在人类免疫缺陷病毒优势准种研究中的准确性[J]. 中华实验和临床感染病杂志(电子版), 2021, 15(01): 22-28.
[10] 施文娟, 张妍, 王兆勋, 万红. 91例丙氨酸氨基转移酶低于正常值上限二倍的慢性乙型肝炎患者肝组织病理特征与实验室指标的相关性[J]. 中华实验和临床感染病杂志(电子版), 2020, 14(02): 138-143.
[11] 毛创杰, 胡蓉, 曾义岚, 张琼, 康信通. 替诺福韦酯对四川地区妊娠中期高HBV载量慢性乙型肝炎孕妇母婴阻断的疗效[J]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 485-490.
[12] 王金环, 于国英, 祖红梅, 杨秀兰, 郭建英, 丁瑞花, 庞玉花, 杨松. 三维显微定量超声在乙型肝炎肝硬化患者病情评价中的应用[J]. 中华实验和临床感染病杂志(电子版), 2019, 13(06): 472-477.
[13] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[14] 李勇, 兰川, 吴斌, 张光年, 李敬东. 术前血小板-白蛋白评分对肝硬化肝癌术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 412-416.
[15] 刀辰冉, 陈义发, 阿力木江·买合木提, 徐磊, 陈姚. S指数对符合米兰标准的肝癌合并慢性乙肝患者术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2021, 10(03): 274-278.
阅读次数
全文


摘要